Ultrasonic analysis of peptide- And antibody-targeted microbubble contrast agents for molecular imaging of α vβ 3-expressing cells

Molecular Imaging

Volumn 3, Issue 2, 2004, Pages 125-136

  Dayton, Paul A ^a   Pearson, David ^a   Clark, Jarrod ^a   Simon, Scott ^a   Schumann, Patricia A ^b   Zutshi, Reena ^b   Matsunaga, Terry O ^b   Ferrara, Katherine W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ImaRx Therapeutics Inc   (United States)

Author keywords

v 3; Angiogenesis; Contrast agent; Integrin; Microbubble; Molecular imaging; Targeted imaging; Ultrasound

Indexed keywords

ΑVΒ3; ANGIOGENESIS; CONTRAST AGENT; INTEGRIN; MICROBUBBLES; MOLECULAR IMAGING; TARGETED IMAGING;

ANTIBODIES; BLOOD VESSELS; BUBBLE FORMATION; CELLS; IMAGE ANALYSIS; MAGNETIC RESONANCE IMAGING; SIGNAL TO NOISE RATIO; TISSUE; ULTRASONIC IMAGING;

PROTEINS;

ANTIBODY; PEPTIDE; VITRONECTIN RECEPTOR;

ARTICLE; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; ECHOGRAPHY; FLOW CYTOMETRY; HUMAN; MELANOMA; METABOLISM; METHODOLOGY; MICROBUBBLE; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE; UMBILICAL VEIN; UPREGULATION; VASCULAR ENDOTHELIUM;

ANTIBODIES; CELL LINE; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHAVBETA3; MELANOMA; MICROBUBBLES; PEPTIDES; SENSITIVITY AND SPECIFICITY; ULTRASONOGRAPHY; UMBILICAL VEINS; UP-REGULATION;

EID: 4644324752     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.1162/1535350041464883     Document Type: Article

References (43)

1. Lanza GM, Wickline SA (2001). Targeted ultrasonic contrast agents for molecular imaging and therapy. Prog Cardiovasc Dis. 44:13-31.
2. Klibanov AL, Hughes MS, Marsh JN, Hall CS, Miller JG, Wible JH, Brandenburger GH (1997). Targeting of ultrasound contrast material. An in vitro feasibility study. Acta Radiol Suppl. 412:113-120.
3. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, Kotyk JJ (2000). Magnetic resonance contrast enhancement of neovasculature with alpha(v)beta(3)-targeted nanoparticles. Magn Reson Med. 44:433-439.
4. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC (1998). Detection of tumor angiogenesis in vivo by alpha Vbeta3-targeted magnetic resonance imaging. Nat Med. 4:623-626.
5. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM (2003). Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63:5838-5843.
6. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA (2003). Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin- targeted nanoparticles. Circulation. 108:2270-2274.
7. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M (2001). Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:1781-1785.
8. Haubner RH, Wester HJ, Weber WA, Schwaiger M (2003). Radiotracer-based strategies to image angiogenesis. Q Nucl Med. 47:189-199.
9. Ellegala DB, Leong-Poi H, Carpenter JE, Klibanov AL, Kaul S, Shaffrey ME, Sklenar J, Lindner JR (2003). Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation. 108:336-341.
10. Leong-Poi H, Christiansen J, Klibanov AL, Kaul S, Lindner JR (2003). Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins. Circulation. 107:455-460.
11. Folkman J (1985). Tumor angiogenesis. Adv Cancer Res. 43:175-203.
12. Folkman J (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol. 3:65-71.
13. Folkman J (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29:15-18.
14. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27-31.
15. Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4-6.
16. Rak JW, St Croix BD, Kerbel RS (1995). Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs. 6:3-18.
17. Brooks PC, Clark RA, Cheresh DA (1994). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 264:569-571.
18. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995). Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest. 96:1815-1822.
19. Gladson CL, Cheresh DA (1991). Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 88:1924-1932.
20. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA (1990). Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 50:6757-6764.
21. Stromblad S, Cheresh DA (1996). Integrins, angiogenesis and vascular cell survival. Chem Biol. 3:881-885.
22. Eliceiri BP, Cheresh DA (1999). The role of alphav integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest. 103:1227-1230.
23. Vamer JA, Cheresh DA (1996). Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Important Adv Oncol. 69-87.
24. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994). Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of anglogenic blood vessels. Cell. 79:1157-1164.
25. Borden MA, Longo ML (2002). Dissolution behavior of lipid monolayer-coated, air-filled microbubbles: Effect of lipid hydrophobic chain length. Langmuir. 18:9225-9233.
26. Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA (1996). A novel site targeted ultrasonic contrast agent with broad biomedical application. Circulation. 94:3334-3340.
27. Schumann PA, Christiansen JP, Quigley RM, McCreery TP, Sweitzer RH, Unger EC, Lindner JR, Matsunaga TO (2002). Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi. Invest Radiol. 37:587-593.
28. Pfaff M, Tangemann K, Muller B, Gurrath M, Muller G, Kessler H, Timpl R, Engel J (1994). Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha lib beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem. 269:20233-20238.
29. Aumailley M, Gurrath M, Muller G, Calvete J, Timpl R, Kessler H (1991). Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett. 291:50-54.
30. Haubner R, Gratias B, Diefenbach B, Goodman SL, Jonczyk A, Kessler H (1996). Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha(v)beta(3) antagonists. J Am Chem Soc. 118:7461-7472.
31. Byzova TV, Kim W, Midura RJ, Plow EF (2000). Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein. Exp Cell Res. 254:299-308.
32. Allman R, Cowburn P, Mason M (2000). In vitro and in vivo effects of a cyclic peptide with affinity for the alpha(nu)beta3 integrin in human melanoma cells. Eur J Cancer. 36:410-422.
33. Pampori N, Hato T, Stupack DG, Aidoudi S, Cheresh DA, Nemerow GR, Shattil SJ (1999). Mechanisms and consequences of affinity modulation of integrin alpha(V)beta(3) detected with a novel patch-engineered monovalent ligand. J Biol Chem. 274:21609-21616.
34. Dayton P, Klibanov A, Brandenburger G, Ferrara K (1999). Acoustic radiation force in vivo: A mechanism to assist targeting of microbubbles. Ultrasound Med Biol. 25:1195-1201.
35. Lele M, Sajid M, Wajih N, Stouffer GA (2001). Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation. 104:582-587.
36. Voura EB, Ramjeesingh RA, Montgomery AM, Siu CH (2001). Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol Biol Cell. 12:2699-2710.
37. Lum AF, Green CE, Lee GR, Staunton DE, Simon SI (2002). Dynamic regulation of LFA-1 activation and neutrophil arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow. J Biol Chem. 277:20660-20670.
38. Marsh JN, Hall CS, Scott MJ, Fuhrhop RW, Gaffney PJ, Wickline SA, Lanza GM (2002). Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model. IEEE Trans Ultrason Ferroelectr Freq Control. 49:29-38.
39. Lindner JR, Dayton PA, Coggins MP, Ley K, Song J, Ferrara K, Kaul S (2000). Noninvasive imaging of inflammation by ultrasound detection of phagocytosed microbubbles. Circulation. 102:531-538.
40. Lanza GM, Trousil RL, Wallace KD, Rose JH, Hall CS, Scott MJ, Miller JG, Eisenberg PR, Gaffney PJ, Wickline SA (1998). In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J Acoust Soc Am. 104:3665-3672.
41. Hall CS, Marsh JN, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM (2000). Time evolution of enhanced ultrasonic reflection using a fibrin-targeted nanoparticulate contrast agent. J Acoust Soc Am. 108:3049-3057.
42. Dayton PA, Morgan KE, Klibanov AL, Brandenburger GH, Ferrara KW (1999). Optical and acoustical observations of the effects of ultrasound on contrast agents. IEEE Trans Ultrason Ferroelectr Freq Control. 46:220-232.
43. Morgan KE, Dayton PA, Kruse DE, Klibanov AL, Brandenburger GH, Ferrara KW (1998). Changes in the echoes from ultrasonic contrast agents with imaging parameters. IEEE Trans Ultrason Ferroelectr Freq Control. 45:1537-1548.